Jeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.
Jeffrey R. Schriber, MD, FRCP
Advertisement
Jeffrey R. Schriber, MD, FRCP is the director of hematologic malignancies at Cancer Treatment Centers of America (CTCA) in Phoenix, Arizona.
Articles by Jeffrey R. Schriber, MD, FRCP
New studies have shown promise for updated standards of care in patients with lymphoma.
Advertisement
Latest Updated Articles
World Lymphoma Day: Advances in Therapy Signal A New Standard of Care for Patients with Hodgkin or Non-Hodgkin LymphomaPublished: September 15th 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
